Advisory Board November 11, 2020
Early data showing Pfizer’s coronavirus vaccine candidate is more than 90% effective turned a lot of heads this week, but experts say the drugmaker faces a number of obstacles in getting its vaccine to the public.
The first hurdle: FDA authorization and manufacturing
Pfizer has said it intends to seek an emergency use authorization from FDA within the next week, once it has a total of two months of safety data. That puts the vaccine on track to be authorized by FDA as early as December, the Wall Street Journal reports.
Once the vaccine is authorized, Pfizer will need to produce massive quantities of the drug. Albert Bourla, Pfizer’s CEO, said that, by the end of the year, the company...
Today's Sponsors
Today's Sponsor